Incyte Corporation (INCY) Return on Assets (ROA): 19.51%
Is Incyte Corporation’s return on assets (ROA) high or low?
Incyte Corporation's return on assets (ROA) of 19.51% is 162% above its 5-year average of 7.44%, near the high end of its 5-year range (-8.30%–19.51%).
As of Sunday, June 21, 2026. 104.40% above its 12-month average of 9.54%.
INCY Return on Assets (ROA) Chart
INCY Average Return on Assets (ROA) Chart
INCY Current vs Average Return on Assets (ROA) Chart
INCY Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
19.51%
RETURN ON ASSETS (ROA) AVG TTM
9.54%
RETURN ON ASSETS (ROA) AVG 3Y
8.43%
RETURN ON ASSETS (ROA) AVG 5Y
7.44%
RETURN ON ASSETS (ROA) AVG 10Y
5.02%
RETURN ON ASSETS (ROA) AVG 15Y
1.09%
RETURN ON ASSETS (ROA) AVG 20Y
-7.51%
CURRENT VS TTM AVG
+104.40%
CURRENT VS 3Y AVG
+131.37%
CURRENT VS 5Y AVG
+162.11%
CURRENT VS 10Y AVG
+288.43%
CURRENT VS 15Y AVG
+1696.50%
CURRENT VS 20Y AVG
+359.82%
INCY Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 19.51% | 9.54% | 8.43% | 7.44% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 4.93% | 4.41% | 4.42% | 6.18% |
| Viatris Inc. (VTRS)vs › | $17.90B | -0.80% | -5.49% | -1.68% | -1.68% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 3.35% | 3.64% | 3.29% | 2.38% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 19.17% | 16.59% | 14.73% | 13.22% |
| BioNTech SE (BNTX)vs › | $22.98B | -6.03% | -3.96% | 9.16% | 17.06% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 23.85% | 25.02% | 24.63% | 23.85% |
| Waters Corporation (WAT)vs › | $23.17B | 1.83% | 13.34% | 15.53% | 17.15% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 10.31% | 9.93% | 9.72% | 10.43% |
Asset Efficiency
ROA
19.5%
ROE
25.8%
Incyte Corporation Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Incyte Corporation (INCY)?
- The return on assets (ROA) for INCY stock is 19.51%.
- Is Incyte Corporation's return on assets (ROA) high or low?
- Incyte Corporation's return on assets (ROA) of 19.51% is 162% above its 5-year average of 7.44%, near the high end of its 5-year range (-8.30%–19.51%).
- What is the TTM average return on assets (ROA) for Incyte Corporation (INCY)?
- The TTM average return on assets (ROA) for INCY stock is 9.54%.
- What is the 3Y average return on assets (ROA) for Incyte Corporation (INCY)?
- The 3Y average return on assets (ROA) for INCY stock is 8.43%.
- What is the 5Y average return on assets (ROA) for Incyte Corporation (INCY)?
- The 5Y average return on assets (ROA) for INCY stock is 7.44%.
- What is the 10Y average return on assets (ROA) for Incyte Corporation (INCY)?
- The 10Y average return on assets (ROA) for INCY stock is 5.02%.
- What is the 15Y average return on assets (ROA) for Incyte Corporation (INCY)?
- The 15Y average return on assets (ROA) for INCY stock is 1.09%.
- What is the 20Y average return on assets (ROA) for Incyte Corporation (INCY)?
- The 20Y average return on assets (ROA) for INCY stock is -7.51%.
Incyte Corporation Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 18.49% |
| 2024-12-31 | 0.60% |
| 2023-12-31 | 8.81% |
| 2022-12-31 | 5.83% |
| 2021-12-31 | 19.23% |
| 2020-12-31 | -8.30% |
| 2019-12-31 | 13.04% |
| 2018-12-31 | 4.14% |
| 2017-12-31 | -13.60% |
| 2016-12-31 | 6.36% |
| 2015-12-31 | 0.65% |
| 2014-12-31 | -5.84% |
| 2013-12-31 | -13.21% |
| 2012-12-31 | -13.41% |
| 2011-12-31 | -56.71% |
| 2010-12-31 | -6.50% |
| 2009-12-31 | -29.74% |
| 2008-12-31 | -76.99% |
| 2007-12-31 | -31.51% |
| 2006-12-31 | -20.97% |
| 2005-12-31 | -27.54% |
| 2004-12-31 | -31.88% |
| 2003-12-31 | -43.86% |
| 2002-12-31 | -24.79% |
| 2001-12-31 | -25.97% |
| 2000-12-31 | -3.35% |
| 1999-12-31 | -12.08% |
| 1998-12-31 | 1.52% |
| 1997-12-31 | 3.57% |
| 1996-12-31 | -10.16% |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury